Business Wire

OPEX® Corporation Announces Key Enhancements to Infinity® Automated Storage and Retrieval System

18.2.2025 10:00:00 CET | Business Wire | Press release

Share

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, is introducing significant enhancements to its Infinity® Automated Storage and Retrieval System (AS/RS). Enhanced features include a 15 percent increase in the system’s storage payload, along with new storage slotting capabilities.

The Infinity AS/RS, launched in 2022, combines unparalleled storage density, configurability and flexibility to meet the most pressing warehouse automation challenges in micro-fulfillment, omni-channel distribution, store replenishment and ecommerce. While the Infinity system was previously capable of supporting 70-pound (31.7 kilogram) payloads, the enhanced system can support 90-pound (40.8 kilogram) payloads. In addition to Infinity iBOT robots now supporting the increased payload, the racking structure, also known as the storage grid, has been updated to manage the increased weight, as well.

“The decision to increase Infinity’s payload has been driven by ongoing inquiries from our manufacturing customers,” explained Monty McVaugh, Head of Product at OPEX. “Many manufacturers want to store large, heavy, metal parts and sub-assemblies on their factory floor, such as alternators, fuel pumps, brake rotors, machining plates and more. The timing for our enhancements to the Infinity system is ideal, as the latest international building codes (IBC2021) outline loads that can be applied to structures, such as high bay storage racking, inside of industrial buildings. The adjustments OPEX has made to the Infinity storage racking comply with IBC2021 in both non-seismic and high-seismic regions.”

Manufacturers often leverage vertical lift modules to accommodate payload capabilities; however, these systems are typically not integrated into the warehouse management system. Accordingly, all transactions must be handled manually via spreadsheets and then imported into other inventory tracking systems. In addition, there is a limited selection of systems on the market that can handle 90 pounds or more per tote, making them capable of leveraging the full height of the warehouse and providing storage density in an efficient manner.

“Our enhanced Infinity AS/RS will also support smaller storage slot spacing,” added Zach Davis, Infinity Product Manager at OPEX. “Many manufacturers prefer to store hardware and fixturing tools on trays. Infinity will now support four-inch storage spacing when trays are utilized, nearly doubling the system’s eight-inch storage density.”

The Infinity goods-to-person (G2P) system utilizes a unique interlocking system to store totes triple-deep, eliminating wasted space and maximizing storage density. A configurable rack design optimizes warehouse space despite obstructions that may exist, such as columns or other equipment. The system’s flexibility also accommodates varied workflows and layouts. Automated G2P technology delivers the right item or SKU at the right time to the right operator or workstation, increasing productivity, throughput and labor utilization by eliminating wasted time.

“Our team at OPEX is always looking for new and better ways to meet evolving customer needs,” said McVaugh. “We’re excited to offer even greater functionality within our Infinity warehouse automation solutions.”

About OPEX

OPEX® Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has nearly 1,600 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and in the future. The year 2025 marks the company’s 50th anniversary under the multigenerational ownership and leadership of the Stevens family.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218613197/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye